Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secretome vs Secretome + TGF-beta 3 for Melasma
NCT07137130Not yet recruiting
- Sponsor
- Universitas Indonesia
- Start
- Feb 2026
- Primary completion
- May 2026
- Modality
- Lipid-based Nanoparticles, Recombinant Proteins and Enzymes, Cell Therapies
- Countries
- 1
01
Overview
Randomised trial of AT-MSC secretome and avotermin in melasma (2 arms), sponsored by Universitas Indonesia. Primary endpoints: Patient's Tolerability Assessment at 84 days, modified Melasma Severity Index at 84 days and 4 more. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
AT-MSC secretomeavotermin
03
Conditions
melasma
Beyond the preview
Go deeper on NCT07137130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07137130.